Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy

Samuel P. Arnot, Gang Han, Jeanine Fortino, Dale Han, Graham Fowler, John T. Vetto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: A 31-gene genetic expression profile (31-GEP; Class 1 = low risk, Class 2 = high risk) developed to predict outcome in cutaneous melanoma (CM) has been validated by retrospective, industry-sponsored, or small series. Methods: Tumor features, sentinel node biopsy (SNB) results, and outcomes were extracted from a prospective database of 383 C M patients who underwent SNB and had a 31-GEP run on their primary tumor. Groups were compared by uni- and multi-variable analysis. Relapse-free and distant metastasis-free survival (RFS, DMFS) were estimated by Kaplan-Meier method. Results: Breslow thickness, T stage, and SNB positivity were significantly higher in Class 2 patients. Recurrence rates were higher for Class 2 vs Class 1 patients and highest in patients who were Class 2 and SNB positive. GEP class was predictive of RFS and DMFS and independently predicted relapse in AJCC “low risk” (stages IA-IIA) patients. Conclusions: 31-GEP adds prognostic information in CM patents undergoing SNB.

Original languageEnglish (US)
Pages (from-to)1195-1199
Number of pages5
JournalAmerican journal of surgery
Volume221
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • Genetic expression profiling
  • Melanoma
  • Outcomes
  • Sentinel node biopsy

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy'. Together they form a unique fingerprint.

Cite this